{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:05:29Z","timestamp":1788822329897,"version":"build-2803163510"},"reference-count":67,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Unleashing adaptive immunity via immune checkpoint inhibitors (ICPIs) in many cancer types led to durable antitumor responses and prolonged survivals and also added some new immune-related adverse events (irAEs) to the \u2018old-fashioned\u2019 safety profile of chemotherapy. Among bowel and endocrine irAEs, immune-mediated hepatotoxicity\/hepatitis is a less common and far less well-studied toxicity, which, however, could develop into a serious complication, especially when it becomes persistent or refractory to steroids. Its incidence, onset and severity vary widely, depending on the type of underlying treated cancer, the class, the dosage and the duration of immunotherapy as well as the way of its administration (as a single agent or in combination with other ICPI or chemotherapy). In this study, we present a patient with metastatic melanoma who developed severe steroid-resistant ir-hepatitis after treatment with ipilimumab and required triple concurrent immunosuppression with prednisolone, mycofenolate mofetil and tacrolimus in order for his liver toxicity to be resolved. Intrigued by this case, we focused further on melanoma, as the disease-paradigm of immunotherapy in cancer, reviewed the reported incidence of hepatotoxicity among phase III ICPIs-containing trials on melanoma and discussed the main clinical considerations regarding the diagnosis and the management of persistent\/steroid-refractory ir-hepatitis. As more clinical experience is gradually gained on this challenging topic, better answers are provided to questions about the appropriate diagnostic workup, the necessity of liver biopsy, the available immunosuppressive options beyond corticosteroids (their combinations and\/or their sequence) as well as the correct decision on withdrawing or resuming immunotherapy. Nonetheless, a thorough multidisciplinary discussion is still required to individualize the overall approach in each case after failure of steroids.<\/jats:p>","DOI":"10.1136\/jitc-2020-001322","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T04:30:14Z","timestamp":1604377814000},"page":"e001322","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report"],"prefix":"10.1136","volume":"8","author":[{"given":"Dimitrios C","family":"Ziogas","sequence":"first","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Gkoufa","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Diamantopoulos","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"2025100302400016000_8.2.e001322.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"2025100302400016000_8.2.e001322.2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174"},{"key":"2025100302400016000_8.2.e001322.3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0038-1667358","article-title":"Liver toxicity with cancer checkpoint inhibitor therapy","volume":"38","author":"Nadeau","year":"2018","journal-title":"Semin Liver Dis"},{"key":"2025100302400016000_8.2.e001322.4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.dld.2019.06.017","article-title":"Hepatotoxicity of immune check point inhibitors: approach and management","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2025100302400016000_8.2.e001322.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"2025100302400016000_8.2.e001322.6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"2025100302400016000_8.2.e001322.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100302400016000_8.2.e001322.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2025100302400016000_8.2.e001322.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100302400016000_8.2.e001322.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100302400016000_8.2.e001322.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PLoS One"},{"key":"2025100302400016000_8.2.e001322.12","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-020-0752-z","article-title":"Gastrointestinal and hepatic complications of immunotherapy: current management and future perspectives","volume":"22","author":"Dougan","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"2025100302400016000_8.2.e001322.13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100302400016000_8.2.e001322.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100302400016000_8.2.e001322.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162"},{"key":"2025100302400016000_8.2.e001322.16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of Immunotherapy-Related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100302400016000_8.2.e001322.17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025100302400016000_8.2.e001322.18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2018.06.012","article-title":"Mortality due to immunotherapy related hepatitis","volume":"69","author":"Bhave","year":"2018","journal-title":"J Hepatol"},{"key":"2025100302400016000_8.2.e001322.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"2025100302400016000_8.2.e001322.20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30678"},{"key":"2025100302400016000_8.2.e001322.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2025100302400016000_8.2.e001322.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"2025100302400016000_8.2.e001322.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025100302400016000_8.2.e001322.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"2025100302400016000_8.2.e001322.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"2025100302400016000_8.2.e001322.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100302400016000_8.2.e001322.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100302400016000_8.2.e001322.28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0717-7"},{"key":"2025100302400016000_8.2.e001322.29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000943"},{"key":"2025100302400016000_8.2.e001322.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025100302400016000_8.2.e001322.31","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"2025100302400016000_8.2.e001322.32","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"2025100302400016000_8.2.e001322.33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","article-title":"Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors","volume":"72","author":"Alessandrino","year":"2017","journal-title":"Clin Radiol"},{"key":"2025100302400016000_8.2.e001322.34","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101146"},{"key":"2025100302400016000_8.2.e001322.35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-Related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"key":"2025100302400016000_8.2.e001322.36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302400016000_8.2.e001322.37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"2025100302400016000_8.2.e001322.38","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32835c7e68"},{"key":"2025100302400016000_8.2.e001322.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"2025100302400016000_8.2.e001322.40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jjco\/hyw167","article-title":"Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab","volume":"47","author":"Tanaka","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2025100302400016000_8.2.e001322.41","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa027","article-title":"Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis","volume":"2020","author":"Nakano","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"2025100302400016000_8.2.e001322.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2025100302400016000_8.2.e001322.43","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-208102"},{"key":"2025100302400016000_8.2.e001322.44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","article-title":"Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins","volume":"81","author":"Sp\u00e4nkuch","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100302400016000_8.2.e001322.45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100302400016000_8.2.e001322.46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep"},{"key":"2025100302400016000_8.2.e001322.47","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?","volume":"70","author":"Riveiro-Barciela","year":"2019","journal-title":"J Hepatol"},{"key":"2025100302400016000_8.2.e001322.48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025100302400016000_8.2.e001322.49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1684\/ejd.2017.2973","article-title":"Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events","volume":"27","author":"Iwamoto","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2025100302400016000_8.2.e001322.50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2025100302400016000_8.2.e001322.51","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144"},{"key":"2025100302400016000_8.2.e001322.52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"2025100302400016000_8.2.e001322.53","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12888"},{"key":"2025100302400016000_8.2.e001322.54","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30991"},{"key":"2025100302400016000_8.2.e001322.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025100302400016000_8.2.e001322.56","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0532-1"},{"key":"2025100302400016000_8.2.e001322.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"2025100302400016000_8.2.e001322.58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130301"},{"key":"2025100302400016000_8.2.e001322.59","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab induces sustained liver injury in a patient with malignant melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern Med"},{"key":"2025100302400016000_8.2.e001322.60","first-page":"2725","article-title":"FK 506 assay past and present--characteristics of FK 506 ELISA","volume":"23","author":"Kobayashi","year":"1991","journal-title":"Transplant Proc"},{"key":"2025100302400016000_8.2.e001322.61","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30689-8"},{"key":"2025100302400016000_8.2.e001322.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2025100302400016000_8.2.e001322.63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539"},{"key":"2025100302400016000_8.2.e001322.64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"2025100302400016000_8.2.e001322.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2025100302400016000_8.2.e001322.66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01381"},{"key":"2025100302400016000_8.2.e001322.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:40:10Z","timestamp":1759484410000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/jitc-2020-001322"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001322","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}